Everolimus Placebo

DRUG8 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Advanced Breast CancerAdvanced Gastric CancerAdvanced Neuroendocrine Tumors of Pancreatic OriginBreast CancerCarcinomaDiffuse Large B-cell LymphomaHepatocellular CarcinomaLymphangioleiomyomatosis (LAM)

Phase 2

Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC

TerminatedNCT01379521

Novartis PharmaceuticalsHepatocellular Carcinoma

Start: 2011-06-30End: 2015-06-30Updated: 2017-05-03

A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

CompletedNCT03312738

Novartis PharmaceuticalsAdvanced Breast Cancer

Start: 2017-09-15End: 2022-04-25Updated: 2024-01-23

Phase 3

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors

CompletedNCT00510068

Novartis PharmaceuticalsAdvanced Neuroendocrine Tumors of Pancreatic Origin

Start: 2007-07-31End: 2014-03-31Updated: 2015-07-01

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

CompletedNCT00790400

Novartis PharmaceuticalsLymphangioleiomyomatosis (LAM), Tuberous Sclerosis Complex (TSC)

Start: 2009-04-30End: 2015-11-30Updated: 2017-02-17

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

CompletedNCT00790036

Novartis PharmaceuticalsDiffuse Large B-cell Lymphoma

Start: 2009-07-24End: 2016-06-15Updated: 2017-07-12

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

CompletedNCT00863655

Novartis PharmaceuticalsBreast Cancer

Start: 2009-06-03End: 2014-12-04Updated: 2017-05-02

Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)

CompletedNCT00879333

Novartis PharmaceuticalsAdvanced Gastric Cancer

Start: 2009-07-31End: 2014-01-31Updated: 2015-11-03

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

CompletedNCT01035229

Novartis PharmaceuticalsCarcinoma

Start: 2010-04-30End: 2013-10-31Updated: 2016-09-22

Related Papers

BOLERO-5: a phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER + /HER2- advanced breast cancer.

2024-06-2114 citations

Serum biomarkers of inflammation (ferritin, IL-8, TNFR1) and outcomes in BOLERO-2, a phase III trial of HR+/HER2- metastatic breast cancer treated with everolimus (mTOR inhibitor).

Journal of Clinical Oncology2020-05-20

Model‐Informed Drug Development for Everolimus Dosing Selection in Pediatric Infant Patients

CPT Pharmacometrics & Systems Pharmacology2020-03-0917 citations

Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis

PLoS ONE2018-09-0730 citations

Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies.

2018-07-1624 citations

Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2

Nephrology Dialysis Transplantation2018-07-1456 citations

Abstract P1-07-09: Serum activin A and outcomes in HR+ /HER2- metastatic breast cancer patients treated with everolimus: Results from BOLERO-2

Cancer Research2018-02-15

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial

Annals of Oncology2017-12-1564 citations

Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex

PLoS ONE2017-10-1218 citations

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study

PLoS ONE2017-08-09162 citations

Prevalence of <i>ESR1</i> Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer

JAMA Oncology2016-08-17477 citations

PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).

Journal of Clinical Oncology2016-05-2018 citations

Correlation of <i>PIK3CA</i> mutations in cell-free DNA (cfDNA) and efficacy of everolimus (EVE) in metastatic breast cancer: Results from BOLERO-2.

Journal of Clinical Oncology2016-05-206 citations

Distinctive chromosomal instability (CIN) patterns and its prognostic value in pancreatic neuroendocrine tumors (pNET).

Journal of Clinical Oncology2016-05-203 citations

Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma.

2016-04-2725 citations

Effect of Everolimus on Subependymal Giant Cell Astrocytoma in Patients Being Treated for Renal Angiomyolipoma: Final Results from EXIST-2 (S34.005)

Neurology2016-04-05

PD04-03 EVEROLIMUS FOR RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TSC OR SLAM: FINAL LONG-TERM RESULTS FROM EXIST-2

The Journal of Urology2016-03-283 citations

Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial

Nephrology Dialysis Transplantation2015-07-08151 citations

Everolimus in patients with advanced, progressive pancreatic neuroendocrine tumors: Overall survival results from the phase III RADIANT-3 study after adjusting for crossover bias.

Journal of Clinical Oncology2015-05-207 citations

Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response

BMC Cancer2015-05-11133 citations

20 more papers not shown